Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario

por Kamel, Dalia, Youssef, Veronica, Hopman, Wilma M., Mates, Mihaela
Publicado 2021

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

por Tu, Megan M., Clemons, Mark, Stober, Carol, Jeong, Ahwon, Vandermeer, Lisa, Mates, Mihaela, Blanchette, Phillip, Joy, Anil Abraham, Aseyev, Olexiy, Pond, Gregory, Fergusson, Dean, Ng, Terry L., Thavorn, Kednapa
Publicado 2021

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage...

por Awan, Arif, Ng, Terry, Conter, Henry, Raskin, William, Stober, Carol, Simos, Demetrios, Pond, Greg, Dhesy-Thind, Sukhbinder, Mates, Mihaela, Kumar, Vikaash, Fergusson, Dean, Hutton, Brian, Saunders, Deanna, Vandermeer, Lisa, Clemons, Mark
Publicado 2020

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

por Clemons, Mark, Liu, Michelle, Stober, Carol, Pond, Gregory, Jemaan Alzahrani, Mashari, Ong, Michael, Ernst, Scott, Booth, Christopher, Mates, Mihaela, Abraham Joy, Anil, Aseyev, Olexiy, Blanchette, Phillip, Vandermeer, Lisa, Tu, Megan, Thavorn, Kednapa, Fergusson, Dean
Publicado 2021

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER...

por Chia, Stephen K., Ellard, Susan L., Mates, Mihaela, Welch, Stephen, Mihalcioiu, Catalin, Miller, Wilson H., Gelmon, Karen, Lohrisch, Caroline, Kumar, Vikaash, Taylor, Sara, Hagerman, Linda, Goodwin, Rachel, Wang, Tao, Sakashita, Shingo, Tsao, Ming S., Eisenhauer, Elizabeth, Bradbury, Penelope
Publicado 2017

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

por Clemons, Mark, Ong, Michael, Stober, Carol, Ernst, Scott, Booth, Christopher, Canil, Christina, Mates, Mihaela, Robinson, Andrew, Blanchette, Phillip, Joy, Anil Abraham, Hilton, John, Aseyev, Olexiy, Pond, Gregory, Jeong, Ahwon, Hutton, Brian, Mazzarello, Sasha, Vandermeer, Lisa, Kushnir, Igal, Fergusson, Dean
Publicado 2021

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

por Ready, Neal, Hellmann, Matthew D., Awad, Mark M., Otterson, Gregory A., Gutierrez, Martin, Gainor, Justin F., Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S., Chesney, Jason, Orcutt, James, Spigel, David R., Reck, Martin, O’Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J., Szustakowski, Joseph D., Green, George, Chang, Han, Ramalingam, Suresh S.
Publicado 2019